Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?"
- PMID: 20160184
- DOI: 10.1161/CIRCINTERVENTIONS.110.936948
Antiplatelet therapy after percutaneous coronary intervention: Should another regimen be "TAPT?"
Comment on
-
Adding cilostazol to dual antiplatelet therapy achieves greater platelet inhibition than high maintenance dose clopidogrel in patients with acute myocardial infarction: Results of the adjunctive cilostazol versus high maintenance dose clopidogrel in patients with AMI (ACCEL-AMI) study.Circ Cardiovasc Interv. 2010 Feb 1;3(1):17-26. doi: 10.1161/CIRCINTERVENTIONS.109.880179. Epub 2010 Jan 26. Circ Cardiovasc Interv. 2010. PMID: 20118150 Clinical Trial.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources